methyl 6-bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: methyl 6-bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxylate
• 化学式: C₉H₇BrN₂O₂
• 分子量: 255.071
• InChiKey: GGPCLKVZVKAFNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-溴-7-氮杂吲哚 、 三氯乙酰氯 在 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 以24%的产率得到methyl 6-bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxylate
  参考文献：
  名称：

  PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES

  摘要：

  该发明涉及6,5杂环环衍生物，其制备方法，含有它们的药物组合物以及它们用于治疗由STING激活驱动的炎症性疾病，如SLE和地理性萎缩症。

  公开号：

  EP3527209A1

文献信息

• Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
  申请人：Kroth Heiko

  公开号：US20110280808A1

  公开（公告）日：2011-11-17

  The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

  本发明涉及一种新型化合物，可用于治疗与淀粉样蛋白相关的一组疾病和异常，如阿尔茨海默病，以及与淀粉样蛋白类似蛋白相关的疾病或病况。本发明的化合物还可用于治疗与视觉系统组织中的病理异常/变化相关的眼部疾病。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于治疗或预防与淀粉样和/或淀粉样类似蛋白相关的疾病或病况的药物的用途。还公开了一种治疗或预防与淀粉样和/或淀粉样类似蛋白相关的疾病或病况的方法。
• NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS
  申请人：AC Immune S.A.

  公开号：EP2558446B1

  公开（公告）日：2019-06-12
• Pharmaceutical 6,5 Heterobicyclic Ring Derivatives
  申请人：UCB Biopharma SRL

  公开号：US20200399268A1

  公开（公告）日：2020-12-24

  The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.
• US9221812B2
  申请人：——

  公开号：US9221812B2

  公开（公告）日：2015-12-29
• [EN] PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES<br/>[FR] DÉRIVÉS CYCLIQUES 6,5 HÉTÉROBICYCLIQUES PHARMACEUTIQUES
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2019158731A1

  公开（公告）日：2019-08-22

  The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.